News briefing: Axovant reports improved motor function in small Parkinson's trial; Bain life sciences SPAC files for $125M IPO
Axovant reported a snapshot of Phase II follow-up data from one cohort in a small Parkinson’s disease trial Tuesday.
The treatment, a gene therapy designed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.